<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Turk J Haematol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Turk J Haematol</journal-id>
      <journal-id journal-id-type="publisher-id">TJH</journal-id>
      <journal-title-group>
        <journal-title>Turkish Journal of Hematology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1300-7777</issn>
      <issn pub-type="epub">1308-5263</issn>
      <publisher>
        <publisher-name>Galenos Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26316491</article-id>
      <article-id pub-id-type="pmc">4451491</article-id>
      <article-id pub-id-type="doi">10.4274/tjh.2014.0436</article-id>
      <article-id pub-id-type="publisher-id">1462</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Platelet Levels of High- and Mega-Dose Methylprednisolone Treatment in Acute Immune Thrombocytopenia</article-title>
        <trans-title-group xml:lang="tr">
          <trans-title>Akut &#x130;mm&#xFC;n Trombositopenide Y&#xFC;ksek ve Megadoz Metilprednizolon Tedavisi ile Trombosit Seviyeleri</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ay&#xE7;i&#xE7;ek</surname>
            <given-names>Ali</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="corresp" rid="COR1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>
Kanuni Sultan S&#xFC;leyman Research and Education Hospital, Clinic of Pediatric Hematology/Oncology, &#x130;stanbul, Turkey
</aff>
      <author-notes>
        <corresp id="COR1">* Address for Correspondence: Kanuni Sultan S&#xFC;leyman Research and Education Hospital, Clinic of Pediatric Hematology/Oncology, &#x130;stanbul, Turkey E-mail: <email>ayciceka@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <volume>32</volume>
      <issue>2</issue>
      <fpage>186</fpage>
      <lpage>187</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>11</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Turkish Journal of Hematology, Published by Galenos Publishing.&#xD;
</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>Immune thrombocytopenic purpura</kwd>
        <kwd>Methylprednisolone</kwd>
        <kwd>Glucocorticoids</kwd>
        <kwd>child</kwd>
        <kwd>adolescent</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>TO THE EDITOR</title>
      <p>High-dose methylprednisolone (HDMP) therapy was originally used by Ozsoylu et al. in the treatment of immune thrombocytopenic purpura (ITP), and it is also important in the history of Turkish hematology [<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref>]. </p>
      <p>A 16-year-old male (weight: 107.5 kg, height: 167 cm, BMI: 38.5 kg/m2) presented with the complaints of oral submucosal bleeding and purpura. Complete blood count analysis revealed a platelet count of 1900/mm3, and his peripheral blood smear and bone marrow aspiration slides were consistent with ITP. Informed consent was obtained for HDMP and MDMP treatment.</p>
      <p>High-dose methylprednisolone was initiated at a dose of 1000 mg/day for 3 days followed by 750 mg/day for 4 days, with each dose administered orally early in the morning. Platelet count reached 28,000/mm3 and 31,000/mm3 on the 3rd and 7th days of&#xA0; treatment, respectively. Mucosal and cutaneous bleeding ceased. Methylprednisolone treatment was continued at a dose of 1 mg/kg/day for 7 days and tapered over a week. Platelet count was 22,000/mm3 on the last day, but bleeding reoccurred 10 days later and platelet count was 3900/mm3. </p>
      <p>Mega-dose methylprednisolone (MDMP) was then given at a dose of 30 mg/kg (3250 mg/day) for 3 days, and then 20 mg/kg (2125 mg/day) for 4 days orally in a single dose in the early morning. Platelet count reached 355,000/mm3, 225,000/mm3, and 381,000/mm3 after 3, 35, and 100 days, respectively (<xref ref-type="fig" rid="f1">Figure 1</xref>). No corticosteroid side effects were observed in this patient [<xref rid="ref3" ref-type="bibr">3</xref>]. There was no thrombocytopenic attack in the last 12 months. </p>
      <p>HDMP treatment has been used as a therapeutic choice in childhood acute ITP in Turkey for a long time [<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref4" ref-type="bibr">4</xref>,<xref rid="ref5" ref-type="bibr">5</xref>]. The term &#x2018;HDMP&#x2019; was used for this kind of methylprednisolone administration initially, but it was later changed to MDMP since &#x2018;HDMP&#x2019; was also used for 4-10 mg/kg doses in the literature [<xref rid="ref6" ref-type="bibr">6</xref>]. It is reported that MDMP treatment differs from conventional corticosteroid (2 mg/kg in divided doses) and pulse methylprednisolone (1000 mg methylprednisolone infusion in 4 h) administration, not only by dose (30-100 mg/kg initially for 3 days, tapered gradually) but also the time of administration [<xref rid="ref7" ref-type="bibr">7</xref>,<xref rid="ref8" ref-type="bibr">8</xref>]. The doses (30 mg/kg for 3 days and 20 mg/kg for 4 days) of methylprednisolone for acute ITP treatment were also originally stated by &#xD6;zsoylu and Ert&#xFC;rk [<xref rid="ref6" ref-type="bibr">6</xref>]. </p>
      <p>Acute ITP is usually a benign, self-limited condition that occurs in young children, typically those younger than 10 years. In the majority of these patients, the thrombocytopenia resolves within weeks or a few months of the original manifestation. Glucocorticoid therapy in symptomatic childhood ITP patients has been suggested as an appropriate first-line therapy [<xref rid="ref2" ref-type="bibr">2</xref>]. Therefore, I think that the results obtained with every high-dose corticosteroid cannot be compared. Based on previous experiences, I wish to conclude that MDMP is a cost-effective treatment for acute ITP, if treatment is required [<xref rid="ref7" ref-type="bibr">7</xref>].</p>
      <p>I would specifically like to emphasize MDMP treatment for these patients, which seems to be the most effective approach in the treatment of this disorder regardless of patient weight. In addition to some reports on intravenous immunoglobulin [<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref>,<xref rid="ref11" ref-type="bibr">11</xref>], MDMP is cheap, safe, and easily applicable in all conditions.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="FN1" fn-type="conflict">
        <p>
          <bold>Conflict of Interest Statement</bold>
        </p>
        <p>The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Ozsoylu</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Bolus methylprednisolone therapy in chronic idiopathic thrombocytopenic purpura in children</article-title>
          <source>Acta Haematol</source>
          <year>1984</year>
          <volume>72</volume>
          <fpage>359</fpage>
          <lpage>360</lpage>
          <pub-id pub-id-type="pmid">6441420</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Ozsoylu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Irken</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Karabent</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>High-dose intravenous methylprednisolone for acute childhood thrombocytopenic purpura</article-title>
          <source>Eur J Haematol</source>
          <year>1989</year>
          <volume>42</volume>
          <fpage>431</fpage>
          <lpage>435</lpage>
          <pub-id pub-id-type="pmid">2731592</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>&#xD6;zsoylu</surname>
              <given-names>&#x15E;</given-names>
            </name>
          </person-group>
          <article-title>Megadose methylprednisolone (MDMP) treatment</article-title>
          <source>Turk J Hematol</source>
          <year>2006</year>
          <volume>23</volume>
          <fpage>120</fpage>
          <lpage>121</lpage>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>&#xD6;zsoylu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Allahverdi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Laleli</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Pirnar</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Platelet survival in childhood idiopathic thrombocytopenic purpura in remission</article-title>
          <source>J Pediatr</source>
          <year>1976</year>
          <volume>89</volume>
          <fpage>388</fpage>
          <lpage>390</lpage>
          <pub-id pub-id-type="pmid">986428</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>&#xD6;zsoylu</surname>
              <given-names>&#x15E;</given-names>
            </name>
            <name>
              <surname>Karabent</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Irken</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tuncer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Antiplatelet antibody in childhood idiopathic thrombocytopenic purpura</article-title>
          <source>Am J Hematol</source>
          <year>1991</year>
          <volume>36</volume>
          <fpage>82</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">2012069</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>&#xD6;zsoylu</surname>
              <given-names>&#x15E;</given-names>
            </name>
            <name>
              <surname>Ert&#xFC;rk</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Oral megadose methylprednisolone for acute childhood idiopathic thrombocytopenic purpura</article-title>
          <source>Blood</source>
          <year>1991</year>
          <volume>77</volume>
          <fpage>1856</fpage>
          <lpage>1857</lpage>
          <pub-id pub-id-type="pmid">2015411</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>&#xD6;zsoylu</surname>
              <given-names>&#x15E;</given-names>
            </name>
          </person-group>
          <article-title>Megadose methylprednisolone for childhood idiopathic thrombocytopenic purpura (ITP)</article-title>
          <source>Turk J Med Sci</source>
          <year>2005</year>
          <volume>35</volume>
          <fpage>347</fpage>
          <lpage>356</lpage>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Engin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>K&#x131;l&#x131;n&#xE7;</surname>
              <given-names>&#xD6;</given-names>
            </name>
            <name>
              <surname>Ozsoylu</surname>
              <given-names>&#x15E;</given-names>
            </name>
          </person-group>
          <article-title>Sa&#x11F;l&#x131;k personelinin serum fizyolojik ile &#xFC;st solunum yollar&#x131; enfeksiyonlar&#x131;ndan korunmas&#x131;</article-title>
          <source>Yeni T&#x131;p Dergisi</source>
          <year>1997</year>
          <volume>14</volume>
          <fpage>211</fpage>
          <lpage>212</lpage>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Simpson</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Coughlin</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Eron</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bussel</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic thrombocytopenia purpura: treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy</article-title>
          <source>Semin Hematol</source>
          <year>1998</year>
          <volume>35(Suppl 1)</volume>
          <fpage>58</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">9523750</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Blackhouse</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Assasi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gaebel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>O&#x2019;Reilly</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tarride</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Goeree</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Canadian cost-utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura</article-title>
          <source>J Popul Ther Clin Pharmacol</source>
          <year>2012</year>
          <volume>19</volume>
          <fpage>e166</fpage>
          <lpage>178</lpage>
          <pub-id pub-id-type="pmid">22580389</pub-id>
        </element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Brien</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Ritchey</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2007</year>
          <volume>48</volume>
          <fpage>173</fpage>
          <lpage>180</lpage>
          <pub-id pub-id-type="pmid">16550529</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <title>Figure 1. Platelet levels during high- and mega-dose methylprednisolone treatment (platelet count x 10<sup>3</sup>/mm<sup>3</sup>).</title>
      </caption>
      <graphic xlink:href="TJH-32-186-g1"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
